肌营养不良

参考文献

关键文献

El-Aloul B, Altamirano-Diaz L, Zapata-Aldana E, et al. Pharmacological therapy for the prevention and management of cardiomyopathy in Duchenne muscular dystrophy: a systematic review. Neuromuscul Disord. 2017 Jan;27(1):4-14. 摘要

King WM, Ruttencutter R, Nagaraja HN, et al. Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy. Neurology. 2007 May 8;68(19):1607-13. 摘要

Forst J, Forst R. Lower limb surgery in Duchenne muscular dystrophy. Neuromuscul Disord. 1999 May;9(3):176-81. 摘要

Buyse GM, Voit T, Schara U, et al. Efficacy of idebenone on respiratory function in patients with Duchenne muscular dystrophy not using glucocorticoids (DELOS): a double-blind randomised placebo-controlled phase 3 trial. Lancet. 2015 May 2;385(9979):1748-57.全文  摘要

Ishikawa Y, Miura T, Ishikawa Y, et al. Duchenne muscular dystrophy: survival by cardio-respiratory interventions. Neuromuscul Disord. 2011 Jan;21(1):47-51. 摘要

Bach JR. A comparison of long-term ventilatory support alternatives from the perspective of the patient and care giver. Chest. 1993 Dec;104(6):1702-6. 摘要

参考文献

1. Hoffman EP, Arahata K, Minetti C, et al. Dystrophinopathy in isolated cases of myopathy in females. Neurology. 1992 May;42(5):967-75. 摘要

2. Zellweger H, Afifi A, McCormick WF, et al. Severe congenital muscular dystrophy. Am J Dis Child. 1967 Dec;114(6):591-602. 摘要

3. Emery AE. Duchenne muscular dystrophy: genetic aspects, carrier detection and antenatal diagnosis. Br Med Bull. 1980 May;36(2):117-22. 摘要

4. Siciliano G, Manca M, Gennarelli M, et al. Epidemiology of myotonic dystrophy in Italy: re-apprisal after genetic diagnosis. Clin Genet. 2001 May;59(5):344-9. 摘要

5. Mostacciuolo ML, Pastorello E, Vazza G, et al. Facioscapulohumeral muscular dystrophy: epidemiological and molecular study in a north-east Italian population sample. Genet. 2009 Jun;75(6):550-5. 摘要

6. van der Kooi AJ. Limb girdle muscular dystrophy (generic term). Orphanet Encyclopedia. Feb 2004 [internet publication].全文

7. Mostacciuolo ML, Miorin M, Martinello F, et al. Genetic epidemiology of congenital muscular dystrophy in a sample from north-east Italy. Hum Genet. 1996 Mar;97(3):277-9. 摘要

8. Aslanidis C, Jansen G, Amemiya C, et al. Cloning of the essential myotonic dystrophy region and mapping of the putative defect. Nature. 1992 Feb 6;355(6360):548-51. 摘要

9. Amato AA, Russell JA. Neuromuscular disorders. New York, NY: McGraw-Hill; 2008.

10. Finsterer J, Stöllberger C, Keller H. Arrhythmia-related workup in hereditary myopathies. J Electrocardiol. 2012 Jul-Aug;45(4):376-84. 摘要

11. Walton JN, Gardner-Medwin D. The muscular dystrophies. In: Walton JN, ed. Disorders of voluntary muscle. 5th ed. Edinburgh, UK: Churchill Livingstone; 1988:519-68.

12. Mascarenhas DA, Spodick DH, Chad DA, et al. Cardiomyopathy of limb-girdle muscular dystrophy. J Am Coll Cardiol. 1994 Nov 1;24(5):1328-33. 摘要

13. McDonald CM, Abresch RT, Carter GT, et al. Profiles of neuromuscular diseases: Duchenne muscular dystrophy. Am J Phys Med Rehabil. 1995 Sep-Oct;74(5 Suppl):S70-92. 摘要

14. Cartegni L, di Barletta MR, Barresi R, et al. Heart-specific localization of emerin: new insights into Emery-Dreifuss muscular dystrophy. Hum Mol Genet. 1997 Dec;6(13):2257-64. 摘要

15. Bach JR, Kang SW. Disorders of ventilation: weakness, stiffness, and mobilization. Chest. 2000 Feb;117(2):301-3.全文  摘要

16. Navarro CT, Teijeira S. Molecular diagnosis of muscular dystrophies, focused on limb girdle muscular dystrophies. Expert Opin Med Diagn. 2009 Nov;3(6):631-47.

17. Tamura T, Shibuya N, Hashiba K, et al. Evaluation of myocardial damage in Duchenne's muscular dystrophy with thallium-201 myocardial SPECT. Jpn Heart J. 1993 Jan;34(1):51-61. 摘要

18. El-Aloul B, Altamirano-Diaz L, Zapata-Aldana E, et al. Pharmacological therapy for the prevention and management of cardiomyopathy in Duchenne muscular dystrophy: a systematic review. Neuromuscul Disord. 2017 Jan;27(1):4-14. 摘要

19. NHS Health Research Authority. Research summaries: DMD-Heart Protection Trial. Feb 2009 [internet publication].全文

20. Ishikawa Y, Bach JR, Minami R. Cardioprotection for Duchenne's muscular dystrophy. Am Heart J. 1999 May;137(5):895-902. 摘要

21. Ishikawa Y, Bach JR. Cardiac management. In: Bach JR. Management of patients with neuromuscular disease. Philadelphia, PA: Hanley & Belfus; 2004:75-104.

22. Maack C, Elter T, Nickenig G, et al. Prospective crossover comparison of carvedilol and metoprolol in patients with chronic heart failure. J Am Coll Cardiol. 2001 Oct;38(4):939-46. 摘要

23. Rhodes J, Margossian R, Darras BT, et al. Safety and efficacy of carvedilol therapy for patients with dilated cardiomyopathy secondary to muscular dystrophy. Pediatr Cardiol. 2008 Mar;29:343-51.

24. Lechtzin N, Shade D, Clawson L, et al. Supramaximal inflation improves lung compliance in subjects with amyotrophic lateral sclerosis. Chest. 2006 May;129(5):1322-9. 摘要

25. Kang SW, Bach JR. Maximum insufflation capacity. Chest. 2000 Jul;118(1):61-5. 摘要

26. Gomez-Merino E, Bach JR. Duchenne muscular dystrophy: prolongation of life by noninvasive ventilation and mechanically assisted coughing. Am J Phys Med Rehabil. 2002 Jun;81(6):411-5.全文  摘要

27. Matthews E, Brassington R, Kuntzer T, et al. Corticosteroids for the treatment of Duchenne muscular dystrophy. Cochrane Database Syst Rev. 2016 May 5;(5):CD003725.全文  摘要

28. Biggar WD, Harris VA, Eliasoph L, et al. Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscul Disord. 2006 Apr;16(4):249-55. 摘要

29. King WM, Ruttencutter R, Nagaraja HN, et al. Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy. Neurology. 2007 May 8;68(19):1607-13. 摘要

30. Bach JR, Martinez D, Saulat B. Duchenne muscular dystrophy: the effect of glucocorticoids on ventilator use and ambulation. Am J Phys Med Rehabil. 2010 Aug;89(8):620-4. 摘要

31. McDonald CM, Henricson EK, Abresch RT, et al. Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study. Lancet. 2018 Feb 3;391(10119):451-61. 摘要

32. Davidson ZE, Truby H. A review of nutrition in Duchenne muscular dystrophy. J Hum Nutr Diet. 2009 Oct;22(5):383-93. 摘要

33. Bello L, Gordish-Dressman H, Morgenroth LP, et al. Prednisone/prednisolone and deflazacort regimens in the CINRG Duchenne Natural History Study. Neurology. 2015 Sep 22;85(12):1048-55.全文  摘要

34. Griggs RC, Miller JP, Greenberg CR, et al. Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy. Neurology. 2016 Nov 15;87(20):2123-31.全文  摘要

35. de Lateur BJ, Giaconi RM. Effect on maximal strength of submaximal exercise in Duchenne muscular dystrophy. Am J Phys Med. 1979 Feb;58(1):26-36. 摘要

36. Voet N, Bleijenberg G, Hendriks J, et al. Both aerobic exercise and cognitive-behavioral therapy reduce chronic fatigue in FSHD: an RCT. Neurology. 2014 Nov 18;83(21):1914-22. 摘要

37. Gianola S, Pecoraro V, Lambiase S, et al. Efficacy of muscle exercise in patients with muscular dystrophy: a systematic review showing a missed opportunity to improve outcomes. PLoS One. 2013 Jun 12;8(6):e65414.全文  摘要

38. Bach JR, McKeon J. Orthopedic surgery and rehabilitation for the prolongation of brace-free ambulation of patients with Duchenne muscular dystrophy. Am J Phys Med Rehabil. 1991 Dec;70(6):323-31. 摘要

39. Forst J, Forst R. Lower limb surgery in Duchenne muscular dystrophy. Neuromuscul Disord. 1999 May;9(3):176-81. 摘要

40. Bach JR, Lieberman JS. Rehabilitation of the patient with disease affecting the motor unit. In: DeLisa JA, ed. Rehabilitation medicine: principles and practice. 2nd ed. Philadelphia, PA: JB Lippincott; 1993:1099-1110.

41. Bach JR, Valenza J, Ogin S. Stage 2: stage of loss of ambulation. In: Bach JR. Management of patients with neuromuscular disease. Philadelphia, PA: Hanley & Belfus; 2004:125-54.

42. Bach JR, Zeelenberg AP, Winter C. Wheelchair-mounted robot manipulators: long term use by patients with Duchenne muscular dystrophy. Am J Phys Med Rehabil. 1990 Apr;69(2):55-9. 摘要

43. Bach JR. Stage 1: the ambulatory stage. In: Bach JR. Management of patients with neuromuscular disease. Philadelphia, PA: Hanley & Belfus; 2004:107-24.

44. Rose KJ, Burns J, Wheeler DM, et al. Interventions for increasing ankle range of motion in patients with neuromuscular disease. Cochrane Database Syst Rev. 2010 Feb 17;(2):CD006973.全文  摘要

45. Bakker JP, de Groot IJ, Beckerman H, et al. The effects of knee-ankle-foot orthoses in the treatment of Duchenne muscular dystrophy: review of the literature. Clin Rehabil. 2000 Aug;14(4):343-59. 摘要

46. Bach JR, Alba AS, Saporito LR. Intermittent positive pressure ventilation via the mouth as an alternative to tracheostomy for 257 ventilator users. Chest. 1993 Jan;103(1):174-82. 摘要

47. Boitano LJ, Jordan T, Benditt JO. Noninvasive ventilation allows gastrostomy tube placement in patients with advanced ALS. Neurology. 2001 Feb 13;56(3):413-4. 摘要

48. Gregory S, Siderowf A, Golaszewski AL, et al. Gastrostomy insertion in ALS patients with low vital capacity: respiratory support and survival. Neurology. 2002 Feb 12;58(3):485-7. 摘要

49. Bach JR, Gonzalez M, Sharma A, et al. Open gastrostomy for noninvasive ventilation users with neuromuscular disease. Am J Phys Med Rehabil. 2010 Jan;89(1):1-6. 摘要

50. Gibson DA, Wilkins KE. The management of spinal deformities in Duchenne muscular dystrophy: a new concept of spinal bracing. Clin Orthop Relat Res. 1975 May;(108):41-51. 摘要

51. Hickey BA, Towriss C, Baxter G, et al. Early experience of MAGEC magnetic growing rods in the treatment of early onset scoliosis. Eur Spine J. 2014 Apr;23 Suppl 1:S61-5.全文  摘要

52. D'Amato CR, Griggs S, McCoy B. Nighttime bracing with the Providence brace in adolescent girls with idiopathic scoliosis. Spine (Phila Pa 1976). 2001 Sep 15;26(18):2006-12. 摘要

53. Thomas MA, Wang Y. Scoliosis and kyphosis. In: Frontera WR, Silver JK, Rizzo TD, eds. Essentials of physical medicine and rehabilitation. 2nd ed. Philadelphia, PA: Saunders Elsevier; 2008:841-47.

54. Brown JC, Zeller JL, Swank SM, et al. Surgical and functional results of spine fusion in spinal muscular atrophy. Spine. 1989 Jul;14(7):763-70. 摘要

55. Ramirez N, Richards BS, Warren PD, et al. Complications after posterior spinal fusion in Duchenne's muscular dystrophy. J Pediatr Orthop. 1997 Jan-Feb;17(1):109-14. 摘要

56. Rideau Y, Glorion B, Delaubier A, et al. Treatment of scoliosis in Duchenne muscular dystrophy. Muscle Nerve. 1984 May;7(4):281-6. 摘要

57. Barnett V, Bach JR. Psychological considerations in the treatment of individuals with generalized neuromuscular disorders. Semin Neurol. 1995 Mar;15(1):58-64. 摘要

58. Bach JR. Update and perspectives on noninvasive respiratory muscle aids. Part 1: the inspiratory aids. Chest. 1994 Apr;105(4):1230-40. 摘要

59. Bach JR, Alba AS. Management of chronic alveolar hypoventilation by nasal ventilation. Chest. 1990 Jan;97(1):52-7. 摘要

60. Mahajan KR, Bach JR, Saporito L, et al. Diaphragm pacing and noninvasive respiratory management of amyotrophic lateral sclerosis/motor neuron disease. Muscle Nerve. 2012 Dec;46(6):851-5. 摘要

61. DiPALS Writing Committee; DiPALS Study Group Collaborators. Safety and efficacy of diaphragm pacing in patients with respiratory insufficiency due to amyotrophic lateral sclerosis (DiPALS): a multicentre, open-label, randomised controlled trial. Lancet Neurol. 2015 Sep;14(9):883-92.全文  摘要

62. Bach JR, Martinez D. Duchenne muscular dystrophy: continuous noninvasive ventilatory support prolongs survival. Respir Care. 2011 Jun;56(6):744-50.全文  摘要

63. Bach JR. Update and perspectives on noninvasive respiratory muscle aids. Part 2: the expiratory aids. Chest. 1994 May;105(5):1538-44. 摘要

64. Bach JR, Gonçalves MR, Hamdani I, et al. Extubation of patients with neuromuscular weakness: a new management paradigm. Chest. 2010 May;137(5):1033-9. 摘要

65. Bach JR, Sinquee DM, Saporito LR, et al. Efficacy of mechanical insufflation-exsufflation in extubating unweanable subjects with restrictive pulmonary disorders. Respir Care. 2015 Apr;60(4):477-83.全文  摘要

66. Bach JR, Saporito LR, Shah HR, et al. Decanulation of patients with severe respiratory muscle insufficiency: efficacy of mechanical insufflation-exsufflation. J Rehabil Med. 2014 Nov;46(10):1037-41.全文  摘要

67. Bach JR. Quality of life and ethical issues. In: Bach JR. The management of patients with neuromuscular disease. Philadelphia, PA: Hanley & Belfus; 2004:331-54.

68. Bach JR, Gonçalves MR, Hon A, et al. Changing trends in the management of end-stage neuromuscular respiratory muscle failure: recommendations of an international consensus. Am J Phys Med Rehabil. 2013 Mar;92(3):267-77. 摘要

69. Iodice F, Testa G, Averardi M, et al. Implantation of a left ventricular assist device as a destination therapy in Duchenne muscular dystrophy patients with end stage cardiac failure: management and lessons learned. Neuromuscul Disord. 2015 Jan;25(1):19-23. 摘要

70. Orrell RW, Copeland S, Rose MR. Scapular fixation in muscular dystrophy. Cochrane Database Syst Rev. 2010 Jan 20;(1):CD003278. 摘要

71. McDonald CM, Campbell C, Torricelli RE, et al. Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017 Sep 23;390(10101):1489-98. 摘要

72. Van Deutekom JC, Janson AA, Ginjaar IB, et al. Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med. 2007 Dec 27;357(26):2677-86.全文  摘要

73. Lim KR, Maruyama R, Yokota T. Eteplirsen in the treatment of Duchenne muscular dystrophy. Drug Des Devel Ther. 2017 Feb 28;11:533-45.全文  摘要

74. Frank DE, Schnell FJ, Akana C, et al. Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy. Neurology. 2020 May 26;94(21):e2270-82.全文  摘要

75. Clemens PR, Rao VK, Connolly AM, et al. Safety, tolerability, and efficacy of viltolarsen in boys with Duchenne muscular dystrophy amenable to exon 53 skipping: a phase 2 randomized clinical trial. JAMA Neurol. 2020 Aug 1;77(8):982-91.全文  摘要

76. ClinicalTrials.gov. Study of SRP-4045 and SRP-4053 in DMD patients (ESSENCE). ClinicalTrials.gov Identifier: NCT02500381. Jul 2020 [internet publication].全文

77. ClinicalTrials.gov. Microdystrophin gene transfer study in adolescents and children with DMD (IGNITE DMD). Jun 2020 [internet publication].全文

78. Solid Biosciences. Solid Biosciences provides SGT-001 program update. Nov 2019 [internet publication].全文

79. ClinicalTrials.gov. Rimeporide in patients with Duchenne muscular dystrophy (RIM4DMD). ClinicalTrials.gov Identifier: NCT02710591. Jul 2019 [internet publication].全文

80. Buyse GM, Voit T, Schara U, et al. Efficacy of idebenone on respiratory function in patients with Duchenne muscular dystrophy not using glucocorticoids (DELOS): a double-blind randomised placebo-controlled phase 3 trial. Lancet. 2015 May 2;385(9979):1748-57.全文  摘要

81. Raman SV, Hor KN, Mazur W, et al. Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2015 Feb;14(2):153-61.全文  摘要

82. Hoffman EP, Schwartz BD, Mengle-Gaw LJ, et al. Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function. Neurology. 2019 Sep 24;93(13):e1312-23.全文  摘要

83. Bettica P, Petrini S, D'Oria V, et al. Histological effects of givinostat in boys with Duchenne muscular dystrophy. Neuromuscul Disord. 2016 Oct;26(10):643-649.全文  摘要

84. ClinicalTrials.gov. Clinical study to evaluate the efficacy and safety of givinostat in ambulant patients with Duchenne muscular dystrophy. Sep 2020 [internet publication].全文

85. ClinicalTrials.gov. A study to evaluate the safety and tolerability of PF-06939926 gene therapy in Duchenne muscular dystrophy. ClinicalTrials.gov Identifier: NCT03362502. Feb 2021 [internet publication].全文

86. Pfizer. Pfizer’s new phase 1b results of gene therapy in ambulatory boys with Duchenne muscular dystrophy (DMD) support advancement into pivotal phase 3 study. May 2020 [internet publication].全文  摘要

87. ClinicalTrails.gov. A phase 3 study to evaluate the safety and efficacy of PF-06939926 for the treatment of Duchenne muscular dystrophy. ClinicalTrials.gov Identifier: NCT04281485. Mar 2021 [internet publication].全文

88. ClinicalTrials.gov. A study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of risdiplam (RO7034067) in type 2 and 3 spinal muscular atrophy (SMA) participants (SUNFISH). ClinicalTrials.gov Identifier: NCT02908685. Jul 2020 [internet publication].全文

89. ClinicalTrials.gov. Investigate safety, tolerability, PK, PD and efficacy of risdiplam (RO7034067) in infants with type 1 spinal muscular atrophy (FIREFISH). ClinicalTrials.gov Identifier: NCT02913482. Aug 2020 [internet publication].全文

90. Baranello G, Darras BT, Day JW, et al. Risdiplam in Type 1 Spinal Muscular Atrophy. N Engl J Med. 2021 Mar 11;384(10):915-923.全文  摘要

91. Wadman RI, van der Pol WL, Bosboom WM, et al. Drug treatment for spinal muscular atrophy types II and III. Cochrane Database Syst Rev. 2020 Jan 6;(1):CD006282.全文  摘要

92. Wadman RI, van der Pol WL, Bosboom WM, et al. Drug treatment for spinal muscular atrophy type I. Cochrane Database Syst Rev. 2019 Dec 11;(12):CD006281.全文  摘要

93. Medicines and Healthcare products Regulatory Agency. Nusinersen (Spinraza▼): reports of communicating hydrocephalus; discuss symptoms with patients and carers and investigate urgently. Sep 2018 [internet publication].全文

94. Hoy SM. Onasemnogene abeparvovec: First global approval. Drugs. 2019 Jul;79(11):1255-62.全文  摘要

95. Prior TW, Leach ME, Finanger, E. Spinal muscular atrophy. In: Adam MP, Ardinger HH, Pagon RA, et al. eds. GeneReviews® [internet]. Seattle, WA: University of Washington, Seattle; 1993-2020.全文  摘要

96. Novartis. Novartis announces AVXS-101 intrathecal study update. Oct 2019 [internet publication].全文

97. Ishikawa Y, Miura T, Ishikawa Y, et al. Duchenne muscular dystrophy: survival by cardio-respiratory interventions. Neuromuscul Disord. 2011 Jan;21(1):47-51. 摘要

98. Bach JR. A comparison of long-term ventilatory support alternatives from the perspective of the patient and care giver. Chest. 1993 Dec;104(6):1702-6. 摘要

99. Hawker GA, Ridout R, Harris VA, et al. Alendronate in the treatment of low bone mass in steroid-treated boys with Duchenne's muscular dystrophy. Arch Phys Med Rehabil. 2005 Feb;86(2):284-8.全文  摘要

100. Bell JM, Shields MD, Watters J,et al. Interventions to prevent and treat corticosteroid-induced osteoporosis and prevent osteoporotic fractures in Duchenne muscular dystrophy. Cochrane Database Syst Rev. 2017 Jan 24;(1):CD010899. 摘要

101. Bach JR, Bardach JL. Neuromuscular diseases. In: Sipski ML, Alexander CJ, eds. Sexual function in people with disability and chronic illness: a health practitioner's guide. Gaithersburg, MD: Aspen; 1997:147-60.

102. Morgenthaler TI, Kapur VK, Brown T, et al; Standards of Practice Committee of the American Academy of Sleep Medicine. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. Sleep. 2007 Dec;30(12):1705-11.全文  摘要

103. Bach JR. The management of patients with neuromuscular disease. Philadelphia, PA: Hanley & Belfus; 2004.

内容使用需遵循免责声明